Induced pluripotent stem cell–derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities
Authors:
- Itziar Uriarte-ArrazolaIUItziar Uriarte-Arrazola
- Míriam Magallón-LorenzMMMíriam Magallón-Lorenz
- Juana Fernández-RodríguezJFJuana Fernández-Rodríguez
- Jiajing ZhangJZJiajing Zhang
- Judit Farrés-CasasJFJudit Farrés-Casas
- Kelli M. WilsonKWKelli M. Wilson
- Katlin RecaboKRKatlin Recabo
- Ignacio BlancoIBIgnacio Blanco
Open Access
- 17 June 2026
- journal article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
Neurofibromatosis Type 1 (NF1) predisposes to peripheral nerve tumor development. The progression from a benign plexiform neurofibroma (PNF) towards a deadly malignant peripheral nerve sheath tumor (MPNST) is not completely understood but commonly involves the sequential loss of NF1, CDKN2A, and polycomb repressive complex 2 (PRC2). Here we use an iPSC-derived neural crest (NC) model to reproduce this malignant transformation through gene editing. NF1-CDKN2A double-knockout (2KO) NCs form neurofibroma-like tumors in vivo, requiring inactivation of p14ARF and p16INK4a. Additional PRC2 loss (3KO) disrupts pluripotency and induces mesenchymal stem cell-like features. 3KO NCs undergo global chromatin reorganization that prevents gliogenesis by SOX10 silencing and activates neuro-mesenchymal transcriptional programs recapitulating PNF-ANNUBP-MPNST progression. Upon nerve engraftment, 3KO NC spheres form MPNST-like tumors in vivo, mimicking an early-stage MPNST. Furthermore, we use the 3D NC spheroid models to discover drugs targeting MPNSTs through high-throughput screening of epigenetic compounds. Poly(ADP-ribose) polymerase inhibitors (PARPi) exhibit selective efficacy in PRC2-deficient NC spheroids and Olaparib-Selumetinib combination is well tolerated and significantly suppresses tumor growth in a human MPNST PDX mouse model.Keywords
Funding Information
- Fundació la Marató de TV3 (51/C/2019)
- Children's Tumor Foundation (CTF-2023-05-001)
- Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (2021 SGR 00967)
- Congressionally Directed Medical Research Programs (NF200051)
- Instituto de Salud Carlos III (FI21/00063)
This publication has 74 references indexed in Scilit:
- A Quantitative High-Throughput Screening Data Analysis Pipeline for Activity Profiling2022
- Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated stateActa Neuropathologica, 2021
- Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiationHuman Genetics, 2021
- Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenograftsPediatric Blood & Cancer, 2020
- Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findingsHuman Mutation, 2018
- Cell of Origin and the Contribution of Microenvironment in NF1 Tumorigenesis and Therapeutic Implications2012
- Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumorsGenes, Chromosomes and Cancer, 2011
- Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival geneEMBO Molecular Medicine, 2009
- Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non‐microdeletion patientsGenes, Chromosomes and Cancer, 2006
- Control of Developmental Regulators by Polycomb in Human Embryonic Stem CellsCell, 2006